Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Oct 21, 5:53 PMQIAGEN and EQT Private Equity announce an agreement on a recommended voluntary all-cash public takeover offer for QIAGEN.
Index
-
Market Cap
10.37B
Enterprise Value
11.22B
Income
409.32M
Sales
2.10B
Book/sh
16.26
Cash/sh
3.85
Employees
5654
IPO
Jun 28, 1996
P/E
25.57
Forward P/E
19.18
PEG
2.97
P/S
4.94
P/B
3.10
P/C
13.07
P/FCF
23.17
EV/EBITDA
15.60
EV/Sales
5.34
Quick Ratio
2.31
Current Ratio
2.85
Debt/Eq
0.49
LT Debt/Eq
0.48
Option/Short
Yes / Yes
EPS (ttm)
1.97
EPS next Y
2.62
EPS next Q
0.63
EPS this Y
2.46%
EPS next Y
7.62%
EPS next 5Y
6.45%
EPS past 3/5Y
-0.15% 3.60%
Sales past 3/5Y
-0.81% 2.25%
EPS Y/Y TTM
9.52%
Sales Y/Y TTM
2.96%
EPS Q/Q
7.13%
Sales Q/Q
0.28%
Insider Own
0.60%
Insider Trans
0.00%
Inst Own
77.59%
Inst Trans
-3.45%
ROA
6.99%
ROE
11.93%
ROIC
8.21%
Gross Margin
61.80%
Oper. Margin
24.62%
Profit Margin
19.49%
SMA20
10.08%
SMA50
13.68%
SMA200
18.42%
Trades
Shs Outstand
206.50M
Shs Float
204.83M
52W High
57.81 -12.92%
52W Low
32.53 54.76%
Volatility
4.44% 3.31%
ATR (14)
1.50
RSI (14)
74.37
Beta
0.60
Rel Volume
16.23
Avg Volume
2.74M
Volume
35,476,684
Perf Week
9.04%
Perf Month
15.18%
Perf Quarter
21.69%
Perf Half Y
32.59%
Perf YTD
12.06%
Perf Year
3.69%
Perf 3Y
34.19%
Perf 5Y
-6.72%
Perf 10Y
95.68%
Prev Close
50.00
Price
50.35
Change %
0.69%
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
CFODr. Roland Sackers
CEO & Member of Management BoardMr. Jonathan M. Pratt
Senior VP & Head of Global OperationsMr. Antonio Santos
CIIAMr. Daniel Wendorff CEFA
VP & Head of Corporate CommunicationsMr. John Gilardi